562
Participants
Start Date
April 30, 2009
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
Colesevelam
Colesevelam 625 mg tablets
Placebo
Placebo tablets appearing to be colesevelam
Pioglitazone
30 mg or 45 mg pioglitazone therapy
North Massapequa
New Windsor
Tonawanda
West Seneca
Upper Saint Clair
Harrisburg
Jersey Shore
Philadelphia
Philadelphia
Manassas
Prince Frederick
Silver Spring
Alexandria
Richmond
Suffolk
Salem
Danville
Lexington
Statesville
Columbia
Charleston
Charleston
Greer
Decatur
Marietta
Roswell
Tucker
Stockbridge
East Point
Waycross
Columbus
Ormond Beach
Jacksonville
Gulf Breeze
DeLand
Sanford
Winter Park
Winter Park
Vero Beach
Hialeah
Pembroke Pines
Pembroke Pines
Coral Gables
Miami
Miami
Miami
Miami
Miami
Wellington
Delray Beach
Tampa
Pinellas Park
Winter Haven
Ocala
New Port Richey
Kissimmee
Birmingham
Birmingham
Birmingham
Montgomery
Montgomery
Murfreesboro
New Tazewell
Germantown
Jackson
Port Gibson
Jackson
Crestview Hills
Paducah
Columbus
Marion
Shaker Heights
Cleveland
Cuyahoga Falls
Stow
Cincinnati
Cincinnati
Cincinnati
La Porte
South Bend
Bloomington
Evansville
Southfield
Kenosha
Brooklyn Center
Billings
Arlington Heights
Chicago
St Louis
Kansas City
Lafayette
Searcy
Oklahoma City
Oklahoma City
Oklahoma City
Grand Prairie
Dallas
Dallas
Dallas
Arlington
Fort Worth
Houston
Houston
Houston
Houston
Tomball
Sugar Land
Sugar Land
San Antonio
San Antonio
Nampa
Salt Lake City
Salt Lake City
Phoenix
Mesa
Tempe
Tempe
Green Valley
Las Vegas
Huntington Park
Buena Park
La Mirada
Lomita
Burbank
Chino
San Diego
Santa Ana
Tustin
Garden Grove
Walnut Creek
Los Gatos
Modesto
Lincoln
Portland
Lakewood
New Bedford
Belvidere
Berlin
Clifton
Lumberton
Mine Hill
Lead Sponsor
Daiichi Sankyo
INDUSTRY